As­traZeneca chops 210 work­ers, clos­es sites as it looks to con­cen­trate bi­o­log­ics man­u­fac­tur­ing in one place

As­traZeneca is clos­ing down two man­u­fac­tur­ing sites in Col­orado that col­lec­tive­ly em­ployed 210 work­ers, in an ap­par­ent ef­fort to con­sol­i­date its bi­o­log­ics sup­ply chain.

First re­port­ed in a WARN no­tice on Tues­day, the lay­offs are “un­re­lat­ed” to the or­ga­ni­za­tion­al changes an­nounced a day pri­or, spokesper­son Michele Meix­ell told me in an email.

The clo­sure of Boul­der and Long­mont is sim­ply a de­ci­sion to con­sol­i­date the bi­o­log­ics man­u­fac­tur­ing net­work in one large-scale drug sub­stance fa­cil­i­ty (our site cur­rent­ly op­er­at­ing in Fred­er­ick, MD) in or­der to im­prove ef­fi­cien­cy in our glob­al bi­o­log­ics sup­ply chain.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER